Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of Parkinson's disease gene therapy.

Trial Profile

Phase III trial of Parkinson's disease gene therapy.

Phase of Trial: Phase III

Latest Information Update: 04 Aug 2011

At a glance

  • Drugs AXO Lenti PD (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 04 Aug 2011 Trial has not yet been initiated.
    • 13 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top